149 related articles for article (PubMed ID: 36907927)
1. Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone.
Omoto T; Asaka J; Nihei S; Kudo K
Support Care Cancer; 2023 Mar; 31(4):208. PubMed ID: 36907927
[TBL] [Abstract][Full Text] [Related]
2. Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care.
Lim KH; Nguyen NN; Qian Y; Williams JL; Lui DD; Bruera E; Yennurajalingam S
J Palliat Med; 2018 Dec; 21(12):1698-1704. PubMed ID: 30260731
[No Abstract] [Full Text] [Related]
3. Intravenous Ketamine for Rapid Opioid Dose Reduction, Reversal of Opioid-Induced Neurotoxicity, and Pain Control in Terminal Care: Case Report and Literature Review.
Winegarden J; Carr DB; Bradshaw YS
Pain Med; 2016 Apr; 17(4):644-9. PubMed ID: 26234740
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Omoto T; Asaka J; Sakai T; Sato F; Goto N; Kudo K
Biol Pharm Bull; 2021; 44(5):627-634. PubMed ID: 33952819
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?
Kanbayashi Y; Hosokawa T
J Palliat Med; 2014 Jun; 17(6):683-7. PubMed ID: 24702605
[TBL] [Abstract][Full Text] [Related]
6. Oxycodone for cancer-related pain.
Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD003870. PubMed ID: 28829910
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
8. Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors.
Kumai M; Imai S; Kato S; Koyanagi R; Tsuruga K; Yamada T; Takekuma Y; Sugawara M
Biol Pharm Bull; 2021; 44(4):593-598. PubMed ID: 33790110
[TBL] [Abstract][Full Text] [Related]
9. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?
Daeninck PJ; Bruera E
Acta Anaesthesiol Scand; 1999 Oct; 43(9):924-38. PubMed ID: 10522740
[TBL] [Abstract][Full Text] [Related]
10. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
Zacny JP; Paice JA; Coalson DW
Pharmacol Biochem Behav; 2012 Jan; 100(3):560-5. PubMed ID: 22085697
[TBL] [Abstract][Full Text] [Related]
11. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Yunusa I; Gagne JJ; Yoshida K; Bykov K
JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series.
Gonzalez A; Walker EJ; Van Loon K; Cinar P; Atreya CE
Anticancer Res; 2020 Feb; 40(2):865-871. PubMed ID: 32014930
[TBL] [Abstract][Full Text] [Related]
13. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
Silvestri B; Bandieri E; Del Prete S; Ianniello GP; Micheletto G; Dambrosio M; Sabbatini G; Endrizzi L; Marra A; Aitini E; Calorio A; Garetto F; Nastasi G; Piantedosi F; Sidoti V; Spanu P
Clin Drug Investig; 2008; 28(7):399-407. PubMed ID: 18544000
[TBL] [Abstract][Full Text] [Related]
14. Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment.
Kokki M; Kuronen M; Naaranlahti T; Nyyssönen T; Pikkarainen I; Savolainen S; Kokki H
Adv Ther; 2017 Jan; 34(1):236-251. PubMed ID: 27921252
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Zin CS; Nissen LM; O'Callaghan JP; Duffull SB; Smith MT; Moore BJ
J Pain; 2010 May; 11(5):462-71. PubMed ID: 19962354
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
17. [Effect of vaginal administration of controlled-release oxycodone on cancer pain].
Zhang X; Ruan XJ; Liu C; Yu ZH
Ai Zheng; 2009 Jul; 28(7):740-2. PubMed ID: 19624902
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study.
Jobski K; Kollhorst B; Garbe E; Schink T
Drug Saf; 2017 Jun; 40(6):505-515. PubMed ID: 28194654
[TBL] [Abstract][Full Text] [Related]
19. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone-induced neurotoxicity secondary to concurrent voriconazole use in a patient with cancer.
Alghothani L; Gustin J
J Opioid Manag; 2017; 13(3):141-142. PubMed ID: 28829515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
